Three Motley Fool contributors look at some of the worst performers of last year and how their fortunes can change in 2015.
A response to a claim that Intel should milk its next-generation processor for 3-4 years.
AMD's turnaround story hasn't exactly started yet. But new CEO Lisa Su just might have what it takes to get the company back on its feet again.
A look at the potential die size and its cost structure implications of Intel's upcoming Xeon Phi processor.
Here’s why Intel’s $149 Windows PC stick matters to ARM Holdings and Google.
Struggling Advanced Micro Devices manages to beat chip giant Intel to the punch in a few areas with its upcoming Carrizo chip.
A look at Advanced Micro Devices' server efforts thus far and what it plans to bring to market.
AbbVie Inc and Gilead Sciences may want to consider Achillion Pharmaceuticals' and Regulus Therapeutics' intriguing hepatitis C drugs.
Celgene Corp, Alkermes, GW Pharmaceuticals, Gilead Sciences, and Hospira should all be on investors radar in 2015.
In phase 3 trials, Alkermes' ALKS-5461 shows promise for the treatment of depression.